Eisai Co., Ltd.
OTC: ESALF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Haruo Naito
- Employees
- 11,067
- Headquarters
- Tokyo, Japan
- IPO year
- 2011
- Market cap
- $7.1B
- Website
- https://www.eisai.co.jp
Loading ESALF…
Loading profile data…Frequently asked questions about ESALF
What does Eisai Co., Ltd. (ESALF) do?
Eisai Co., Ltd., a pharmaceutical company headquartered in Tokyo, Japan, develops and markets a wide array of medicinal products. Its offerings for neurological conditions include Aricept, prescribed for Alzheimer's disease and dementia with Lewy bodies; Methycobal, used to treat peripheral neuropathy; Fycompa, an antiepileptic drug that serves...
Where does ESALF trade?
Eisai Co., Ltd. (ESALF) trades on the Other OTC.
What sector is ESALF in?
Eisai Co., Ltd. (ESALF) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Eisai Co., Ltd.?
Haruo Naito is the chief executive officer of Eisai Co., Ltd. (ESALF).
Where is Eisai Co., Ltd. headquartered?
Eisai Co., Ltd. is headquartered in Japan.
Does ESALF pay a dividend?
Yes — Eisai Co., Ltd. (ESALF) paid a trailing twelve-month dividend of USD 1.04 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did ESALF go public?
Eisai Co., Ltd. (ESALF) completed its initial public offering in 2011.